SurvivorNet on MSN
Targeted therapy in a shot: New approval for EGFR-mutated lung cancer can improve day-to-day life for patients
Rybrevant Faspro, the new subcutaneous version of amivantamab, was approved for patients with a specific form of lung cancer ...
Treatment with Opdivo (nivolumab) and chemotherapy did not significantly improve progression-free survival when compared with chemotherapy alone among some patients with EGFR-mutated metastatic ...
Incorporating β2-microglobulin and β-trace protein filtration markers may improve GFR estimation in patients with solid tumors. Adding the novel endogenous filtration markers β2-microglobulin and ...
Patritumab deruxtecan showed no overall survival benefit over chemotherapy in EGFR mutation-positive NSCLC patients. The drug demonstrated a slight progression-free survival advantage and higher ...
CAMBRIDGE, Mass., Oct. 26, 2022 /PRNewswire/ -- Theseus Pharmaceuticals, Inc. (NASDAQ: THRX) (Theseus or the Company), a clinical-stage biopharmaceutical company focused on improving the lives of ...
DEAR DR. ROACH: I am a 73-year-old female. A recent blood test returned an eGFR (estimated glomerular filtration rate) of 59. My physician’s nurse told me that the test was normal. When I asked her ...
Bispecific antibody targeting of CD47/CD19 to promote enhanced phagocytosis of patient B lymphoma cells. This is an ASCO Meeting Abstract from the 2015 ASCO Annual Meeting I. This abstract does not ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback